Kane Biotech Inc (KNE) - Cash Flow Conversion Efficiency

Latest as of December 2025: 0.912x

Based on the latest financial reports, Kane Biotech Inc (KNE) has a cash flow conversion efficiency ratio of 0.912x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-680.61K ≈ $-492.35K USD) by net assets (CA$-746.54K ≈ $-540.04K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Kane Biotech Inc for the company's overall valuation and market capitalisation.

Kane Biotech Inc - Cash Flow Conversion Efficiency Trend (2003–2025)

This chart illustrates how Kane Biotech Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Kane Biotech Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Kane Biotech Inc ranked by their cash flow conversion efficiency. Explore Kane Biotech Inc cash earnings quality to measure how well operating cash flow supports reported net income.

Company Cash Flow Conversion Efficiency
Euroespes S.A.
MC:EEP
0.003x
Chrysalis Investments Ltd
LSE:CHRY
-0.008x
Osia Hyper Retail Limited
NSE:OSIAHYPER
-0.012x
Madoro Metals Corp
V:MDM
-0.030x
Soco Corporation Ltd
AU:SOC
-0.288x
Biotron Ltd
AU:BIT
-0.322x
International Lithium Corp
V:ILC
-0.028x
Inix Technologies Holdings Bhd
KLSE:0094
0.015x

Annual Cash Flow Conversion Efficiency for Kane Biotech Inc (2003–2025)

The table below shows the annual cash flow conversion efficiency of Kane Biotech Inc from 2003 to 2025. View KNE stock price for real-time trading data and today's change.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 CA$-746.54K
≈ $-540.04K
CA$-3.26 Million
≈ $-2.35 Million
4.361x +72.80%
2024-12-31 CA$-1.63 Million
≈ $-1.18 Million
CA$-4.11 Million
≈ $-2.97 Million
2.523x +919.19%
2023-12-31 CA$-8.41 Million
≈ $-6.08 Million
CA$-2.08 Million
≈ $-1.51 Million
0.248x -66.34%
2022-12-31 CA$-4.14 Million
≈ $-2.99 Million
CA$-3.04 Million
≈ $-2.20 Million
0.736x -49.65%
2021-12-31 CA$-1.57 Million
≈ $-1.13 Million
CA$-2.29 Million
≈ $-1.66 Million
1.461x +139.86%
2020-12-31 CA$1.07 Million
≈ $777.45K
CA$-3.94 Million
≈ $-2.85 Million
-3.665x -221.02%
2019-12-31 CA$836.81K
≈ $605.33K
CA$-955.37K
≈ $-691.10K
-1.142x -139.40%
2018-12-31 CA$-984.84K
≈ $-712.42K
CA$-2.85 Million
≈ $-2.06 Million
2.898x +488.15%
2017-12-31 CA$2.74 Million
≈ $1.98 Million
CA$-2.04 Million
≈ $-1.48 Million
-0.747x +57.43%
2016-12-31 CA$1.35 Million
≈ $974.76K
CA$-2.36 Million
≈ $-1.71 Million
-1.754x +39.34%
2015-12-31 CA$480.25K
≈ $347.40K
CA$-1.39 Million
≈ $-1.00 Million
-2.891x -265.11%
2014-12-31 CA$1.32 Million
≈ $958.43K
CA$-1.05 Million
≈ $-758.95K
-0.792x +12.89%
2013-12-31 CA$1.28 Million
≈ $928.25K
CA$-1.17 Million
≈ $-843.79K
-0.909x -84.75%
2012-12-31 CA$2.35 Million
≈ $1.70 Million
CA$-1.16 Million
≈ $-835.72K
-0.492x -24.43%
2011-12-31 CA$2.38 Million
≈ $1.72 Million
CA$-940.30K
≈ $-680.20K
-0.395x +41.91%
2010-12-31 CA$1.16 Million
≈ $841.74K
CA$-792.06K
≈ $-572.96K
-0.681x -60.08%
2009-12-31 CA$1.80 Million
≈ $1.30 Million
CA$-764.26K
≈ $-552.85K
-0.425x +40.87%
2008-12-31 CA$1.49 Million
≈ $1.08 Million
CA$-1.07 Million
≈ $-776.48K
-0.719x -2.74%
2007-12-31 CA$1.14 Million
≈ $825.19K
CA$-798.38K
≈ $-577.53K
-0.700x -18.27%
2006-12-31 CA$1.42 Million
≈ $1.03 Million
CA$-843.13K
≈ $-609.91K
-0.592x +25.57%
2005-12-31 CA$1.02 Million
≈ $735.99K
CA$-808.87K
≈ $-585.12K
-0.795x +32.63%
2004-12-31 CA$426.65K
≈ $308.63K
CA$-503.50K
≈ $-364.22K
-1.180x -178.44%
2003-12-31 CA$955.27K
≈ $691.03K
CA$-404.87K
≈ $-292.88K
-0.424x --

About Kane Biotech Inc

V:KNE Canada Biotechnology
Market Cap
$3.95 Million
CA$5.46 Million CAD
Market Cap Rank
#29122 Global
#1340 in Canada
Share Price
CA$0.03
Change (1 day)
+0.00%
52-Week Range
CA$0.02 - CA$0.05
All Time High
CA$0.40
About

Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, a biofilm destabilizing formula with continuous activity; and DispersinB technology, a naturally occurring enzyme that cleaves the … Read more